Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evalua...

Source: Annals of Intensive Care - February 11, 2023 Category: Intensive Care Authors: Ignacio Martin-Loeches, Andrew F. Shorr, Richard G. Wunderink, Marin H. Kollef, Jean-Fran çois Timsit, Brian Yu, Jennifer A. Huntington, Erin Jensen and Christopher J. Bruno Tags: Research Source Type: research